Enersyn Global Inc. (ESYN) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Enersyn Global Inc. (ESYN) stock forecast summary
Our AI scores Enersyn Global Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Enersyn Global Inc. is a small-cap company with a market capitalization of $45M. It ranks number 6 by market capitalization among the 7 Wholesale-Drugs, Proprietaries & Druggists' Sundries issuers in our coverage with a current forecast.
For ESYN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 42.0%, measured on 266 forecast dates between 2024-05-17 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 309 forecast dates between 2024-05-17 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ESYN included.
ESYN price chart and AI forecast
How ESYN ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Enersyn Global Inc. (ESYN) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Wholesale-Drugs, Proprietaries & Druggists' Sundries peers listed below that report each metric.
Valuation & Market
| Metric | ESYN | Rank |
|---|---|---|
| Market Cap | $45M | 6/7 |
| P/B Ratio | 16.42x | – |
| Book Value/Share | $0.09 | – |
| Revenue/Share | $0.01 | – |
| FCF/Share | $-0.03 | – |
Profitability & Margins
| Metric | ESYN | Rank |
|---|---|---|
| ROE | -93.7% | – |
| ROA | -56.8% | 6/6 |
| Gross Margin | 59.2% | 3/7 |
| Net Margin | -657.6% | 7/7 |
| EBT Margin | -659.8% | 7/7 |
| Tax Rate | -1.9% | – |
Financial Health
| Metric | ESYN | Rank |
|---|---|---|
| Current Ratio | 1.82x | 2/7 |
| Quick Ratio | 1.81x | 1/7 |
| D/E Ratio | 0.63x | – |
| Financial Leverage | 1.65x | – |
| Working Capital | $1M | 4/7 |
Cash Flow
| Metric | ESYN | Rank |
|---|---|---|
| Operating Cash Flow | -$940K | 6/7 |
| Free Cash Flow | -$960K | 4/5 |
| Capital Spending | -$20K | 1/5 |
| FCF/Sales | -245.1% | 5/5 |
| CapEx/Sales | 4.8% | 1/5 |
Operational Efficiency
| Metric | ESYN | Rank |
|---|---|---|
| Asset Turnover | 0.09x | 5/5 |
| Receivables Turnover | 96.2x | 1/5 |
| Inventory Turnover | 93.8x | 1/7 |
| Fixed Assets Turnover | 26.6x | 3/5 |
| Days Sales Outstanding | 4 days | 5/5 |
| Days Inventory | 4 days | 7/7 |
Income Statement
| Metric | ESYN | Rank |
|---|---|---|
| Total Revenue | $390K | 5/5 |
| Net Income | -$3M | 5/7 |
| Cost of Goods Sold | $140K | 7/7 |
Dividend & Shareholder Information
| Metric | ESYN | Rank |
|---|---|---|
| Shares Outstanding | 30M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $3M | 66.8% of assets |
| Cash & Short-term Investments | $2M | 34.0% of assets |
| Accounts Receivable | $0.00M | 0.0% of assets |
| Inventory | $0.00M | 0.0% of assets |
| Total Liabilities | $2M | 38.5% of assets |
ESYN quarterly financials and insider trading
Enersyn Global Inc. (ESYN) industry peers
Companies classified under the same SEC industry code as Enersyn Global Inc. (Wholesale-Drugs, Proprietaries & Druggists' Sundries): 7 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere ESYN sits on the market map
Enersyn Global Inc. (ESYN) stock news
Loading...
Enersyn Global Inc. (ESYN) stock forecast FAQ
What is the Enersyn Global Inc. (ESYN) stock forecast?
Our AI scores Enersyn Global Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Enersyn Global Inc. stock predictions?
For ESYN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 42.0%, measured on 266 forecast dates between 2024-05-17 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 309 forecast dates between 2024-05-17 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Enersyn Global Inc. forecasts updated?
Enersyn Global Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Enersyn Global Inc.'s industry peers?
7 issuers in our coverage, ESYN included, share the SEC industry code Wholesale-Drugs, Proprietaries & Druggists' Sundries. The largest are: Mckesson Corp (MCK), Cencora, Inc. (COR), Cardinal Health Inc (CAH), Herbalife Ltd. (HLF), Nu Skin Enterprises, Inc. (NUS), Cosmos Health Inc. (COSM).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.